Venture Partners V Lp Skyli... Net Worth

The estimated Net Worth of Venture Partners V Lp Skyli... is at least $67.6 Million dollars as of 19 October 2018. Venture Skyli owns over 325,000 units of SI-BONE Inc stock worth over $66,653,374 and over the last 11 years Venture sold SIBN stock worth over $976,583.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Venture Skyli SIBN stock SEC Form 4 insiders trading

Venture has made over 3 trades of the SI-BONE Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Venture bought 325,000 units of SIBN stock worth $4,875,000 on 19 October 2018.

The largest trade Venture's ever made was buying 325,000 units of SI-BONE Inc stock on 19 October 2018 worth over $4,875,000. On average, Venture trades about 187,511 units every 573 days since 2014. As of 19 October 2018 Venture still owns at least 4,419,985 units of SI-BONE Inc stock.

You can see the complete history of Venture Skyli stock trades at the bottom of the page.

Insiders trading at SI-BONE Inc

Over the last 6 years, insiders at SI-BONE Inc have traded over $114,943,926 worth of SI-BONE Inc stock and bought 1,250,000 units worth $18,750,000 . The most active insiders traders include David P Bonita, Advisors Llc Orbi Med Capit..., and John Gordon Freund. On average, SI-BONE Inc executives and independent directors trade stock every 8 days with the average trade being worth of $401,535. The most recent stock trade was executed by Anshul Maheshwari on 3 September 2024, trading 1,414 units of SIBN stock currently worth $23,119.

What does SI-BONE Inc do?

si-bone® is focused on helping patients in one of the most under-served, under-diagnosed, and under-treated areas in orthopedics, the sacroiliac (si) joint. si-bone developed an innovative, patented implant to fuse the si joint. the ifuse implant system® provides a less invasive alternative to traditional sacroiliac (si) joint fusion surgery and has been used in over 25,000 procedures to date. the company is managed by an experienced team of executives from kyphon, medtronic, inbone, saint francis and several start up orthopedic and spine companies. the ifuse implant system is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. this includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months. there are potential risks associated with the ifuse implant system. it may not be appropriate for al

Complete history of Venture Skyli stock trades at Dicerna Pharmaceuticals Inc and SI-BONE Inc

SI-BONE Inc executives and stock owners

SI-BONE Inc executives and other stock owners filed with the SEC include:

• Aleksey Miller,
  Non-Executive Chairman of the Board
• Mikhail Sereda,
  Non-Executive Director
• Elena Mikhailova,
  Non-Executive Director
• Valery Serdyukov,
  Non-Executive Director
• Kirill Seleznev,
  Non-Executive Director
• Andrey Dmitriev,
  Non-Executive Director
• Vladimir Alisov,
  Non-Executive Director
• Laura A. Francis,
  CEO & Director
• Anthony J. Recupero,
  Pres of Commercial Operations
• Anshul Maheshwari,
  Chief Financial Officer
• Famil Sadygov,
  Non-Executive Director
• Sergey Menshikov,
  Non-Executive Director
• Aleksandr Medvedev,
  Non-Executive Director
• Vitaly Markelov,
  Non-Executive Director
• Sergey Kuznetsov,
  Non-Executive Director
• Viktoriya Nenadyshina,
  Secretary to the Board of Directors
• Aleksey Yankevich,
  Member of the Management Board, Deputy Chief Executive Officer for Economics and Finance
• Kirill Kravchenko,
  Member of the Management Board, Deputy Chief Executive Officer for Administration
• Pavel Kolobkov,
  Deputy Chief Executive Officer for Federal Government Relations, Member of the Management Board
• Elena Ilyukhina,
  Deputy Chief Executive Officer for Legal and Corporate Affairs, Member of the Management Board
• Aleksandr Dybal,
  Member of the Management Board, Deputy Chief Executive Officer for Corporate Communications
• Igor Antonov,
  Deputy Chief Executive Officer for Security, Member of the Management Board
• Vadim Yakovlev,
  Deputy Chief Executive Officer of Upstream, Deputy Chairman of the Management Board
• Anatoly Cherner,
  Deputy Chairman of the Management Board, Deputy Chief Executive Officer for Logistics, Processing and Sales (Downstream)
• Aleksandr Dyukov,
  Executive Director, General Director (Chief Executive Officer), Chairman of the Management Board
• Dr. Daniel Joseph Cher,
  Sr. VP of Clinical & Regulatory Affairs
• Joyce Goto,
  VP & Corp. Controller
• Nikolas F. Kerr,
  Sr. VP of Product, Strategy & Bus. Devel.
• Dr. W. Carlton Reckling,
  Chief Medical Officer & VP of Medical Affairs
• Joseph W. Powers,
  VP of Corp. Marketing
• Dr. Scott A. Yerby,
  Sr. VP of Engineering & CTO
• Michael A. Pisetsky,
  Sr. VP of Operations & Admin., Sec. and Chief Legal Officer
• Venture Partners V Lp Skyli...,
  
• Michael A Pisetsky,
  SVP, Ops & Adm/Chief Legal Ofr
• Anthony J Recupero,
  President, Commercial Ops
• David P Bonita,
  Director
• Venture Partners V Lp Skyli...,
  
• Keith Valentine,
  
• Scott A Yerby,
  Chief Technology Officer
• Timothy Petersen,
  Director
• John Gordon Freund,
  
• Timothy E Jr Davis,
  
• Mark A Reiley,
  Director
• Advisors Llc Orbi Med Capit...,
  
• Equity Partners Iv, L.P.Mon...,
  
• Gregory K Hinckley,
  
• Jeryl L Hilleman,
  
• Mark J Foley,
  
• Heyward R Donigan,
  
• Karen A Licitra,
  
• Jeffrey W Dunn,
  
• W Carlton Reckling,
  CMO and VP, Medical Affairs
• Venture Partners V Lp Freun...,
  
• Helen Loh,
  
• Mika Nishimura,
  
• Anshul Maheshwari,
  Chief Financial Officer
• Laura Francis,
  Chief Executive Officer
• Thomas A. West,
  
• Daniel W Wolf,